Lv73
4330 积分 2023-03-05 加入
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
12天前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
14天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
14天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
14天前
已完结
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
14天前
已完结
RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT
19天前
已完结
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease
20天前
已完结
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
22天前
已完结
A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD
22天前
已完结
Treatment of severe hidradenitis Suppurativa and Fistulizing Crohn’s disease with Guselkumab
29天前
已完结
皖公网安备34019202002308
